These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25092700)

  • 1. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.
    Lepak AJ; Reda A; Marchillo K; Van Hecker J; Craig WA; Andes D
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6311-4. PubMed ID: 25092700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
    MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
    Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA; Bassetti M; Duncan LR; Castanheira M
    J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
    Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6305-10. PubMed ID: 24100499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae.
    McGee L; Biek D; Ge Y; Klugman M; du Plessis M; Smith AM; Beall B; Whitney CG; Klugman KP
    Antimicrob Agents Chemother; 2009 Feb; 53(2):552-6. PubMed ID: 19015339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.
    Craig WA; Andes DR
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1577-82. PubMed ID: 23274659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.
    Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumoniae with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Winterfield P; Biek D; Rybak MJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2691-5. PubMed ID: 22354289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
    Hyatt JM; Nix DE; Schentag JJ
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2730-7. PubMed ID: 7695254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
    mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A; Tan E; McCarthy KL; Paterson DL
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
    Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC; Lee YJ; Huang YT; Liao CH; Tsuji M; Hsueh PR
    J Antimicrob Chemother; 2019 Feb; 74(2):380-386. PubMed ID: 30357343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.